Practice Point®: Rare Diseases

Managing uncontrolled gout isn’t always straightforward—especially when flares persist, comorbidities complicate care, or standard therapies fall short. As our understanding of gout expands beyond just elevated uric acid, clinicians are being asked to think differently, integrating immune pathways, real-world evidence, and emerging treatments into everyday practice. From Refractory to Resolved: Re...

Managing uncontrolled gout isn’t always straightforward—especially when flares persist, comorbidities complicate care, or standard therapies fall short. As our understanding of gout expands beyond just elevated uric acid, clinicians are being asked to think differently, integrating immune pathways, real-world evidence, and emerging treatments into everyday practice. From Refractory to Resolved: Re...

Managing uncontrolled gout isn’t always straightforward—especially when flares persist, comorbidities complicate care, or standard therapies fall short. As our understanding of gout expands beyond just elevated uric acid, clinicians are being asked to think differently, integrating immune pathways, real-world evidence, and emerging treatments into everyday practice. From Refractory to Resolved: Re...

These podcast episodes explore the rapidly evolving treatment landscape of Primary Biliary Cholangitis, highlighting recent therapeutic advances and reviews emerging clinical evidence on promising investigational therapies. Designed for healthcare professionals, these episodes provides expert commentary on the latest cutting-edge data presented at EASL Congress 2026. Through an engaging podcast fo...

These podcast episodes explore the rapidly evolving treatment landscape of Primary Biliary Cholangitis, highlighting recent therapeutic advances and reviews emerging clinical evidence on promising investigational therapies. Designed for healthcare professionals, these episodes provides expert commentary on the latest cutting-edge data presented at EASL Congress 2026. Through an engaging podcast fo...

Leveraging emerging evidence presented at AAN, Dr. Angela Hirbe provides synthesis of key findings, highlight their relevance across pediatric and adult care, and frame practical considerations for patient assessment and longitudinal management. Launch/Release Date: April 24, 2026 Activity Expiration Date: March 31, 2027 FACULTY Angela Hirbe, MD, PhD Associate Professor of Medicine and Pediatrics...

Clinical care for myasthenia gravis is entering a period of meaningful progress, with growing opportunities to improve how the disease is diagnosed, assessed, and treated. Increased awareness of disease heterogeneity and the expanding use of standardized severity assessments are helping clinicians better define disease burden and guide management decisions. In this 20-minute podcast episode, Dr. J...

This activity will provide a comprehensive overview of NF1-PN and will dive deeper into the nuances of treating and managing adult patients with inoperable symptomatic NF1-PN. Dr. Angela Hirbe will use clinical cases to illustrate best-practice approaches to optimally identify adult patients with NF1-PN that will benefit from approved MEK inhibitors and will detail how to choose between agents and...

This activity will inform participants about the complex pathophysiology of NF1-PN and how an understanding of molecular pathways has led to the development of MEK inhibitors. The key published and ongoing clinical evidence on the utility of approved and emerging therapies for NF1-PN will be detailed to provide a strong foundation for clinical decision-making. An in-depth guide to recognize and di...

Gout remains the most common form of inflammatory arthritis in adults, yet it continues to be one of the most misunderstood and mismanaged chronic diseases in clinical practice. Despite clear treatment guidelines and a growing array of therapeutic options, a substantial proportion of patients experience persistent flares, disease progression, and comorbid complications due to clinical inertia, fra...

Stay informed on the go with our expert-led podcast series dedicated to stroke prevention. Across seven short episodes, Dr.'s C. Michael Gibson and Manesh Patel explore the shifting landscape of antithrombotic therapy—especially the potential role of Factor XIa inhibitors. From trial data to clinical applications, this series distills what you need to know to enhance patient care and reduce stroke...

Stay informed on the go with our expert-led podcast series dedicated to stroke prevention. Across seven short episodes, Dr.'s C. Michael Gibson and Manesh Patel explore the shifting landscape of antithrombotic therapy—especially the potential role of Factor XIa inhibitors. From trial data to clinical applications, this series distills what you need to know to enhance patient care and reduce stroke...

Stay informed on the go with our expert-led podcast series dedicated to stroke prevention. Across seven short episodes, Dr.'s C. Michael Gibson and Manesh Patel explore the shifting landscape of antithrombotic therapy—especially the potential role of Factor XIa inhibitors. From trial data to clinical applications, this series distills what you need to know to enhance patient care and reduce stroke...

Stay informed on the go with our expert-led podcast series dedicated to stroke prevention. Across seven short episodes, Dr.'s C. Michael Gibson and Manesh Patel explore the shifting landscape of antithrombotic therapy—especially the potential role of Factor XIa inhibitors. From trial data to clinical applications, this series distills what you need to know to enhance patient care and reduce stroke...

Stay informed on the go with our expert-led podcast series dedicated to stroke prevention. Across seven short episodes, Dr.'s C. Michael Gibson and Manesh Patel explore the shifting landscape of antithrombotic therapy—especially the potential role of Factor XIa inhibitors. From trial data to clinical applications, this series distills what you need to know to enhance patient care and reduce stroke...

Stay informed on the go with our expert-led podcast series dedicated to stroke prevention. Across seven short episodes, Dr.'s C. Michael Gibson and Manesh Patel explore the shifting landscape of antithrombotic therapy—especially the potential role of Factor XIa inhibitors. From trial data to clinical applications, this series distills what you need to know to enhance patient care and reduce stroke...

Stay informed on the go with our expert-led podcast series dedicated to stroke prevention. Across seven short episodes, Dr.'s C. Michael Gibson and Manesh Patel explore the shifting landscape of antithrombotic therapy—especially the potential role of Factor XIa inhibitors. From trial data to clinical applications, this series distills what you need to know to enhance patient care and reduce stroke...

The introduction of kinase inhibitors has significantly impacted the treatment landscape of plexiform neurofibromas (PN) associated with neurofibromatosis type 1 (NF1). In this podcast activity from the 2025 Annual Oncology Meeting, noteworthy data in NF1-PN has been summarized and evaluated by Dr. Amy Armstrong. This activity is AMA/ABS/ANCC/ACPE accredited for one-year. Launch Date: June 5, 2025...

There continues to be significant progress in the treatment of primary biliary cholangitis (PBC) and these Clinical Clips from EASL 2025 have focused on the most impactful data presented at this conference. Dr. Nancy Reau will summarize key advances from Day 2 of EASL 2025 and describe their implications for clinical practice. Launch Date: May 13, 2025 Release Date: May 13, 2025 Expiration Date: A...

There continues to be significant progress in the treatment of primary biliary cholangitis (PBC) and these Clinical Clips from EASL 2025 have focused on the most impactful data presented at this conference. Dr. Nancy Reau will summarize key advances from Day 1 of EASL 2025 and describe their implications for clinical practice. Launch Date: May 13, 2025 Release Date: May 13, 2025 Expiration Date: A...

In this podcast titled "Emerging Evidence in Myasthenia Gravis: Key Updates from AAN 2025," Dr. Nicholas Silvestri provides healthcare professionals with an actionable update on recent advancements in MG; which features insights from groundbreaking research presented at AAN 2025. Launch Date: April 30, 2025 Release Date: April 30, 2025 Expiration Date: March 31, 2026 FACULTY Nicholas Silvestri, MD...

Join Dr. Nicholas Silvestri in this 8-minute, special edition podcast series on myasthenia gravis (MG). Today’s podcast titled, The Future of MG Care: Innovations in Diagnostics and Guidelines , looks ahead at emerging technologies and the need for standardized international guidelines to harmonize MG management. Launch Date: April 28, 2025 Release Date: April 28, 2025 Expiration Date: March 31, 2...

Join Dr. Nicholas Silvestri in this 9-minute, special edition podcast series on myasthenia gravis (MG). Today’s podcast titled, Tailoring Treatment: The Role of Serotype Testing , discusses the impact of serotype testing on treatment decisions, including differences in therapeutic approaches for AChR-positive, MuSK-positive, and LRP4-positive patients. Launch Date: April 24, 2025 Release Date: Apr...

Join Dr. Nicholas Silvestri in this 10-minute, special edition podcast series on myasthenia gravis (MG). Today’s podcast titled, Innovations in MG Therapeutics , focuses on the latest therapies, including complement inhibitors and FcRn antagonists, and their application in personalized treatment plans. Launch Date: April 21, 2025 Release Date: April 21, 2025 Expiration Date: March 31, 2026 FACULTY...

Join Dr. Nicholas Silvestri in this 8-minute, special edition podcast series on myasthenia gravis (MG). Today’s podcast titled, Advancements in Myasthenia Gravis Diagnosis , highlights the limitations of traditional diagnostic methods and introduces emerging technologies such as high-sensitivity serotype testing and advanced neurophysiological techniques. Launch Date: April 17, 2025 Release Date:...